Please try another search
| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| LUPNc1:NS | NSE | INR | Delayed | |
| LUPN | NSE | INR | Real-time | |
| LUPNc2:NS | NSE | INR | Delayed | |
| LUPNc3:NS | NSE | INR | Delayed | |
| LUPN | BSE | INR | Delayed |
Lupin Limited (500257, NSE: LUPIN) announced that results from its Phase 1a trial of LNP8701, an experimental cancer treatment, have been presented at the American Society of...
Lupin Limited (500257, NSE: LUPIN) announced it received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for Famotidine Injection USP, 20 mg/2...
GuruFocus - Total Revenue from Operations: INR 7,475 crore for Q4 FY26, a 32% year-on-year growth.EBITDA: INR 2,171 crore for Q4 FY26, a 68% year-on-year increase.EBITDA Margin:...
Amphastar Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company known for developing, manufacturing, and marketing injectable, inhalation, and intranasal products...
| Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Filter Table By:
| Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
|---|---|---|---|---|---|
| Completed Patterns | |||||
| Doji Star Bearish | 1W | 1 | Jul 05, 2026 | ||
| Three Inside Down | 1D | 2 | Jul 13, 2026 | ||
| Gravestone Doji | 1W | 3 | Jun 21, 2026 | ||
| Three Inside Up | 1H | 3 | Jul 14, 2026 23:00 | ||
| Engulfing Bearish | 15 | 3 | Jul 15, 2026 01:45 | ||
| Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| NSE | 2,485.60 | 2,485.70 | 2,487.90 | 198,475 | +1.00% | INR | 02:34:29 | ||
| NSE | 2,504.90 | 2,504.60 | 2,504.70 | 356,896 | +1.45% | INR | 02:50:31 | ||
| NSE | 2,490.60 | 2,485.60 | 2,490.60 | 33,150 | +1.10% | INR | 02:29:29 | ||
| NSE | 2,496.20 | 2,491.80 | 2,500.80 | 2,975 | +0.86% | INR | 01:37:25 | ||
| BSE | 2,502.65 | 2,501.30 | 2,502.75 | 8,204 | +1.34% | INR | 02:35:28 |
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| Canadian Natural | 60.00 | 61.40 | 59.62 | -0.95 | -1.56% | 15.33M | 14/07 | ||
| Air Canada | 22.87 | 23.79 | 22.84 | -0.81 | -3.42% | 2.23M | 14/07 | ||
| Toronto Dominion Bank | 172.81 | 173.34 | 170.76 | +2.12 | +1.24% | 10.35M | |||
| BCE Inc | 29.81 | 30.25 | 29.73 | -0.59 | -1.94% | 4.76M | 14/07 | ||
| TELUS | 14.69 | 14.87 | 14.68 | -0.22 | -1.48% | 5.24M | 14/07 | ||
| Bank of Nova Scotia | 125.25 | 126.10 | 124.25 | +0.78 | +0.63% | 2.98M | 14/07 | ||
| Keel Infra | 6.30 | 6.66 | 6.23 | +0.13 | +2.11% | 3.26M | 14/07 | ||
| Canadian Imperial Bank | 166.68 | 168.28 | 165.97 | +0.71 | +0.43% | 1.14M | 14/07 | ||
| MDA | 47.66 | 47.91 | 45.42 | +2.98 | +6.67% | 1.58M | 14/07 | ||
| Celestica Inc. | 485.06 | 497.65 | 481.31 | -3.46 | -0.71% | 197.30K |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women’s health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review